

SENTARA COMMUNITY PLAN (MEDICAID)

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-844-305-2331. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. If information provided is not complete, correct, or legible, authorization can be delayed.

Drug Requested: Imaavy™ (nipocalimab-aahu) IV (J9256) (Medical)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

Weight (if applicable): _____ Date weight obtained: _____

- Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.

Recommended Dosage:

- **Initial dosage:** 30 mg/kg via intravenous (IV) infusion over at least 30 minutes.
- **Maintenance dosage:** 2 weeks after initial dose, administer 15 mg/kg via IV infusion over at least 15 minutes. Continue maintenance dosage every 2 weeks thereafter.

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Initial Authorization: 6 months

- Prescribing physician must be a neurologist
- Member must be 12 years of age or older
- Member must have Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Class II to IV disease and have a positive serologic test for anti-acetylcholine receptor (AChR) antibodies or anti-muscle-specific tyrosine kinase (MuSK) antibodies (**lab test must be submitted**)
- Physician has assessed objective signs of neurological weakness and fatigability on a baseline neurological examination (e.g., including but not limited to the Quantitative Myasthenia Gravis (QMG) score) (**chart notes must be submitted**)
- Member has a baseline MG-Activities of Daily Living (MG-ADL) total score of at least 6 (**results must be submitted**)
- Member must meet **ONE** of the following (**verified by chart notes or pharmacy paid claims**):
 - Member has tried and had an inadequate response to pyridostigmine
 - Member has an intolerance, hypersensitivity, or contraindication to pyridostigmine
- Member must meet **ONE** of the following (**verified by chart notes or pharmacy paid claims**):
 - Adults with AChR+ disease:** member failed over 1 year of therapy with at least 2 immunosuppressive therapies (e.g., azathioprine, cyclosporine, mycophenolate)
 - Adults with MuSK+ disease:** member failed over 1 year of therapy with immunosuppressive therapy (e.g., corticosteroids, azathioprine, or mycophenolate) **in addition to rituximab AND Rystiggo[®]**
 - Member required at least one acute or chronic treatment with plasmapheresis, plasma exchange (PE) or intravenous immunoglobulin (IVIG) in addition to the member's therapy required above
 - Pediatrics with AChR+ or MuSK+ disease** between 12 and 17 years of age and meet **ONE** of the following:
 - Member with AChR+ disease:** a minimum one-year trial of concurrent use with an oral corticosteroid plus another immunosuppressive therapy (e.g., azathioprine, cyclosporine, mycophenolate, etc.)
 - Member with MuSK+ disease:** a minimum one-year trial with immunosuppressive therapy (e.g., corticosteroids, azathioprine, or mycophenolate) and rituximab
 - Member required at least one acute or chronic treatment with plasmapheresis or plasma exchange (PE) or intravenous immunoglobulin (IVIG) in addition to immunosuppressant therapy

(Continued on next page)

- Member will avoid or use with caution medications known to worsen or exacerbate symptoms of MG (e.g., aminoglycosides, fluoroquinolones, beta-blockers, botulinum toxins, hydroxychloroquine)
- Member does **NOT** have an active infection, including clinically important localized infections
- Requested medication will **NOT** be administered with live-attenuated or live vaccines during treatment
- Medication will **NOT** be used in combination with other immunomodulatory biologic therapies (e.g., rituximab, eculizumab, ravulizumab, rozanolixizumab, zilucoplan, efgartigimod alfa-fcab, efgartigimod alfa and hyaluronidase-qvfc, inebilizumab-cdon)

Reauthorization: 6 months. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- Member continues to meet all initial authorization criteria
- Member has **NOT** experienced unacceptable toxicity from the drug (e.g., infections, severe hypersensitivity reactions infusion reactions, aseptic meningitis)
- Member meets **ONE** of the following:
 - Member has demonstrated an improvement of at least 2 points in the MG-ADL total score from baseline sustained for at least 4 weeks (**results must be submitted to document improvement**)
 - Member has demonstrated an improvement of at least 3 points from baseline in the Quantitative Myasthenia Gravis (QMG) total score sustained for at least 4 weeks (**results must be submitted to document improvement**)
 - Member requires continuous treatment, after initial beneficial response, due to new or worsening disease activity

EXCLUSIONS – Therapy will NOT be approved if member has history of any of the following:

- MGFA Class I or MG crisis at initiation of treatment (MGFA Class V)
- Use of rituximab within 6 months prior to treatment
- Use of IVIG or PE within 4 weeks prior to treatment
- Any active or clinically significant infections that have not been treated

(Continued on next page)

Medication being provided by: Please check applicable box below.

- Location/site of drug administration: _____
NPI or DEA # of administering location: _____

OR

- Specialty Pharmacy

For urgent reviews: Practitioner should call Sentara Health Plans Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara Health Plan's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****
****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****